CRL4^Cdt2 Ubiquitin Ligase, A Genome Caretaker Controlled by Cdt2 Binding to PCNA and DNA

Area of Science:

• Cell Biology
• Molecular Biology
• Genomics

Background:

• The CRL4^Cdt2 ubiquitin ligase is crucial for genomic integrity, controlling proteins during S phase and DNA damage.
• Its deregulation can lead to DNA re-replication, promoting cancer development.
• Key substrates include Cdt1, Set8, and p21, which are vital for DNA replication.

Purpose of the Study:

• To review the structural and functional features of Cdt2, the substrate receptor for CRL4^Cdt2.
• To elucidate the mechanism by which Cdt2 regulates CRL4 ubiquitination activity.
• To explore the therapeutic potential of targeting Cdt2 domains in cancer treatment.

Main Methods:

• This review synthesizes existing research on CRL4^Cdt2 and its substrate receptor Cdt2.
• Analysis of Cdt2's N-terminal and C-terminal domains, including substrate recognition, intrinsically disordered regions (IDRs), phosphorylation sites, PIP box, and DNA binding domains.
• Literature review focusing on the functional implications of these domains in CRL4 ubiquitination.

Main Results:

• Cdt2 possesses distinct domains (N-terminal, C-terminal) that modulate CRL4 ubiquitination.
• Specific features like the substrate recognition domain, IDR, phosphorylation sites, PIP box, and DNA binding domain are critical for Cdt2 function.
• These domains dictate substrate binding and CRL4 activity, impacting cell cycle regulation.

Conclusions:

• Cdt2's structural features are key to CRL4^Cdt2's role in genomic stability.
• Targeting specific Cdt2 domains offers a promising strategy for developing novel cancer therapeutics.
• Further research into Cdt2 mechanisms could unlock new avenues for cancer treatment.